Welcome, we OEM manufacturer wholesale price
+86-755-23577295
An aging population, reduced outdoor time, sedentary lifestyles, and unhealthy eating habits have led to a gradual increase in the number of people suffering from visual impairment. Retinal diseases are the leading cause of visual impairment and blindness worldwide, among which glaucoma ranks first in the world and is irreversible. Glaucoma is the number one cause of blindness. Data based on population prevalence models predict that by 2040, 112 million people over the age of 40 will be affected by glaucoma.
Nutritional factors are associated with a variety of eye and vision diseases, and in recent years nutritional supplements, which provide neuroprotective and antioxidant factors, have been used to aid the progressive loss of glaucoma.
Citicoline has been studied in the field of ophthalmology for 30 years and has been widely used in the treatment of glaucoma in recent years. Citicoline has the effect of protecting nerves, restoring nerves and regenerating nerves in the visual system. Supplementing citicoline can improve cholinergic system dysfunction, further enhance visual function, and slow down the progression of glaucoma. In Italy, citicoline has been approved as a dietary supplement for special medical purposes in glaucoma patients.
Glutathione is an important antioxidant in the human body and plays many key functions in the central nervous system. Adult mammalian brains contain high levels of glutathione, with the highest absorption rate of glutathione in the retina.
Studies have found that glutathione levels in glaucoma patients are much lower than those in non-glaucoma controls. Glutathione deficiency makes cells susceptible to damage, which is related to a variety of eye diseases. Glutathione supplementation can prevent free radicals Damage caused by oxidative stress caused by oxidants, oxidants, and toxic xenobiotics. Most importantly, glutathione plays a key role in maintaining mitochondrial function. Increasing the mitochondrial GSH pool may prevent mitochondrial dysfunction-related Retinal diseases.
We are an enterprise integrating R&D, production and sales. The company has achieved commercial production of reduced glutathione, Nicotinamide Mononucleotide, and citicoline sodium. The products are exported to more than 70 countries and regions around the world and are well received by customers. If you are interested in our products If you are interested, please contact us.
[1] Musa M, Zeppieri M, Atuanya GN, Enaholo ES, Topah EK, Ojo OM, Salati C. Nutritional Factors: Benefits in Glaucoma and Ophthalmologic Pathologies. Life (Basel). 2023 Apr 30;13(5):1120. doi: 10.3390/life13051120. PMID: 37240765; PMCID: PMC10222847.
[2] Tham YC, Li :2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26. PMID: 24974815.
[3] van der Merwe Y, Murphy MC, Sims JR, Faiq MA, Yang XL, Ho LC, Conner IP, Yu Y, Leung CK, Wollstein G, Schuman JS, Chan KC. Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control. Neurotherapeutics. 2021 Apr;18(2):1339-1359. doi: 10.1007/s13311-021-01033-6. Epub 2021 Apr 13. PMID: 33846961; PMCID: PMC8423893.
[4] Iskusnykh IY, Zakharova AA, Pathak D. Glutathione in Brain Disorders and Aging. Molecules. 2022 Jan 5;27(1):324. doi: 10.3390/molecules27010324. PMID: 35011559; PMCID: PMC8746815.
[5] Sreekumar PG, Ferrington DA, Kannan R. Glutathione Metabolism and the Novel Role of Mitochondrial GSH in Retinal Degeneration. Antioxidants (Basel). 2021 Apr 24;10(5):661. doi: 10.3390/antiox10050661. PMID: 33923192 ; PMCID: PMC8146950.
